Abstract: The present invention relates to acne and rosacea compositions by a six-prong synergistic combination treatment strategy that includes (1) control of excess sebum production, (2) control of undesirable bacteria or mites, (3) control of inflammation, (4) enhanced desquamation of follicular infundibulum cells, (5) reduction of irritation from anti-acne or rosacea compositions themselves, and (6) enhancement of the topical bioavailability of anti-acne and rosacea compositions. This is achieved by a synergistic combination of commonly utilized topical anti-acne and rosacea ingredients with a topical bioavailability enhancement composition, which results in enhanced anti-acne and rosacea action from such ingredients. Moreover, additional inclusion of an anti-inflammatory composition, and also a vascular micro-circulation enhancement composition, further results in synergistic superior anti-acne and rosacea benefits from such compositions.
Abstract: A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's electric properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biologically active molecule moiety and the cinnamic acid backbone. The biologically active molecule can be any biologically active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, campotothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug composition can be modified to add a carrier moiety on the prodrug composition for targeting or to facilitate uptake of the drug. The prodrug compositions can be activated with an energy source to release the drug at the desired site.
Type:
Grant
Filed:
January 31, 2002
Date of Patent:
August 10, 2004
Assignee:
Cryolife, Inc.
Inventors:
Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
Abstract: The invention relates to the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for the preparation of a medication for the preventive therapy for pain.
Abstract: The invention relates to powdered preparations for inhalation containing a tiotropium salt and salmeterol xinafoate, processes for preparing them and their use in the preparation of a pharmaceutical composition for treating respiratory diseases, particularly for treating COPD (chronic obstructive pulmonary disease) and asthma.
Type:
Application
Filed:
December 15, 2003
Publication date:
August 5, 2004
Applicant:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Mareke Hartig, Michael Trunk, Rainer Soyka, Peter Sieger, Hagen Graebner, Michael Walz
Abstract: The invention relates to the use of the acetyl L-carnitine in association with the biotin for the treatment of patients, with type 2 insulin-resistant diabetes mellitus.
Abstract: Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.
Type:
Application
Filed:
December 23, 2003
Publication date:
July 15, 2004
Applicants:
ChanTest, Inc., Government of the United States of America
Abstract: A composition includes acetyl-L-carnitine or its pharmacologically acceptable salt and a mixture of polyphenols containing hydroxytyrosol in an effective weight ratio. Carnitine can be L-carnitine, propionyl-L-carnitine, valeryl-L-carnitine, isovaleryl-L-carnitine or mixtures thereof. The composition has a weight ratio of carnitine:hydroxytyrosol of from 100:1 to 1:10. Also disclosed is a method of preventing tissue damage caused by the presence of free radicals due to environmental pollution; of preventing brain or myocardial lesions induced by free radicals following cerebral or myocardial ischemia and reperfusion; of preventing diabetic or toxic neuropathies and metabolic disorders of glucose utilization, which includes administering the composition.
Abstract: Novel compounds and pharmaceutical compositions containing such compounds and possessing anti-tussive activity, and a method of administering the same to warm-blooded animals, including humans.
Type:
Application
Filed:
December 23, 2003
Publication date:
July 1, 2004
Inventors:
Gregory N. Beatch, Lewis S. L. Choi, Clive P. Page, Bertrand M. C. Plouvier, Yuzhong Liu
Abstract: The present invention relates to a pharmaceutical solution containing a physiologically active non-peptide substance, an organic acid and a biocompatible organic solvent, and provides a pharmaceutical solution wherein a physiologically active non-peptide substance is dissolved at a high concentration.
Abstract: Compounds are disclosed with the general formula A-B, which in the vicinity of tumor cells result in a positively charged moiety B and an uncharged or negatively charged moiety A. Moiety B is able to induce blood clotting by interacting with negatively charged heparin-like substances lining vascular endothelia and the positive charge is reversibly masked by the uncharged or negatively charged moiety A in order to prevent unspecific disseminated blood coagulation and toxicity. Moiety B is either a covalent assembly of positively charged chemical groups or a positively charged molecule, which in aqueous solutions forms non-covalent polycations due to its propensity to form intermolecular aggregates. Pharmaceutical compositions including the compound and a pharmaceutically acceptable adjuvant or excipient are also disclosed. The disclosed compounds are useful in medicine, in particular for the manufacture of a medicament and its use for the treatment of a subject.
Abstract: The invention relates to an octenidine antiseptic for wounds and mucous membranes that is characterized by a content in ethanol and a physiologically acceptable organic acid.
Abstract: This invention relates to in-situ preparation of the derivatives of various hydroxy acids (HA), such as &agr;-(Alpha) Hydroxy Acids (AHA), &bgr;-(Beta) Hydroxy Acids (BHA), and Poly-Hydroxy Acids (PHA) with certain skin beneficial organic hetero-atom bases and their application in skin resurfacing (exfoliation), and in the synergistic treatment and regulation of topical disorders of skin such as skin aging, wrinkles, acne, rosacea, age-spots, canker sores, striae distensae (stretch marks), pimples, skin redness, and dry skin conditions of cracking, flaking, and scaling. Most HA derivatives produced by the in-situ method do not cause skin irritation and skin redness effects that are commonly experienced with AHA and BHA, yet there is no loss of their skin beneficial effects.
Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.
Abstract: The invention is directed to novel and advantageous pharmaceutical compositions for oral administration of the antidepressant compound paroxetine. The composition is in the form of a tablet having a dissolution rate of at least 90% in 30 minutes measured with a paddle apparatus according to US Pharmacopoeia.
Type:
Application
Filed:
December 23, 2003
Publication date:
May 6, 2004
Inventors:
Theodorus Hendricus Antonius Peters, Frans van Dalen, Jacobus Maria Lemmens, Frantisek Picha
Abstract: Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.
Abstract: The invention relates to addition and/or co-ordination compounds consisting of creatine and citric acid in the ratio of >1.0 to 3.0:1.0. Said compounds are characterised in that they have (KBr) bands in the IR spectrum, where &ngr;=3425 (±5) cm−1 (s), 1624 (±5) cm−1 (m-s) and 1247 (±5) cm−1 (m). Said compounds, which preferably contain no organic solvent and are present in a solid, pulverulent form are produced in particular by a method, according to which, a1) creatine, containing a maximum content of 20 wt. % water, is reacted with citric acid or its salts at temperatures between 0 and 70° C., or a2) creatine and citric acid or its salts, containing a total water content of between 5 and 15 wt. %, are ground at temperatures between 0 and 70° C., or a3) creatine is reacted with citric acid or its salts, in the presence of a solvent at temperatures between 0 and 70° C. The corresponding solvent is then eliminated to a maximum residual content of 1.
Type:
Application
Filed:
October 31, 2003
Publication date:
April 22, 2004
Inventors:
Ralf Jager, Martin Purpura, Gunter Ortenburger
Abstract: This invention discloses the hydrosoluble creatine salt dicreatine maleate, and a method for manufacturing same. Creatine is a popular ergogenic aid, and is found most often in the form of creatine monohydrate. Creatine monohydrate is poorly soluble in water however, prompting this inventor to search for a more suitable form of creatine for nutritional supplementation. Dicreatine maleate offers a level of water solubility more than 12 fold better than creatine monohydrate.
Abstract: The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.
Type:
Application
Filed:
August 15, 2003
Publication date:
April 22, 2004
Inventors:
Johannes Bartholomaus, Elmar Josef Friderichs
Abstract: A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.
Abstract: The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate.
Type:
Application
Filed:
October 3, 2003
Publication date:
April 8, 2004
Inventors:
Jae-Heon Lee, Gha-Seung Park, Jae-Cheol Lee, Han-Kyong Kim, Young-Kil Chang, Gwan-Sun Lee
Abstract: The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug (“NSAID”). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses.
Abstract: A non-toxic, germicide, fungicide and healing composition and a method of topically applying the composition in powdered form to the skin of domesticated farm animals including dairy cattle are disclosed. The composition comprises (a) finely divided, particulate chlorhexidine-containing material, (b) finely divided, particulate zinc-containing material and (c) an inert powdered carrier, with the chlorhexidine-containing material and the zinc-containing material being present in an amount to achieve effective germicidal activity. The chlorhexidine-containing material is preferably chlorhexidine acetate. The zinc-containing material is preferably selected from the group consisting of zinc stearate, zinc chloride, zinc nitrate, zinc oleate, zinc oxide, zinc phosphate, zinc peroxide, zinc iodide, elemental zinc and mixtures thereof.
Abstract: A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
Type:
Application
Filed:
January 29, 2003
Publication date:
March 25, 2004
Applicant:
SHIRE LABORATORIES, INC.
Inventors:
Richard A. Couch, Beth Burnside, Rong-Kun Chang
Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
Abstract: An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
Type:
Application
Filed:
August 14, 2003
Publication date:
March 11, 2004
Applicant:
Chiesi Farmaceutici S.p.A.
Inventors:
David Lewis, David Ganderton, Brian Meakin, Gaetano Brambilla, Alessandra Ferraris
Abstract: External preparations for the skin which contain, as active ingredients, substances capable of preventing a reduction in the expression of the filaggrin gene in cultured human keratinocytes as induced by exposure to a gaseous phase (for example, betaines, polyols, crude drugs, and substances having an antioxidant action).
Type:
Application
Filed:
June 27, 2003
Publication date:
March 4, 2004
Inventors:
Chika Katagiri, Tetsuji Hirao, Hiroshi Fujita, Nobuyoshi Koga
Abstract: A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.
Type:
Application
Filed:
August 20, 2003
Publication date:
February 26, 2004
Inventors:
George V. Guittard, Francisco Ja, Susan M. Marks, David J. Kidney, Fernando E. Gumucio
Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.
Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.
Type:
Application
Filed:
June 23, 2003
Publication date:
February 5, 2004
Inventors:
Torbjorn Lundstedt, Anna Skottner, Elisabeth Seifert
Abstract: The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.
Type:
Application
Filed:
July 3, 2002
Publication date:
January 15, 2004
Inventors:
Fang-Yu Lee, Shan-Chiung Chen, Ping-Kuen Chen, Han-Chiang Kuo
Abstract: The present invention relates to ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate], the preparation of ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate] from (2R)-2-bromo-3-phenylpropionic acid and ethylenediamine in 2-propanol, and the use of ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate] for the preparation of ACE/NEP inhibitors.
Type:
Application
Filed:
March 17, 2003
Publication date:
January 15, 2004
Inventors:
Javier Manero, Tobias Metzenthin, Rainer Gauler
Abstract: The invention relates to choline pyruvate of formula (I) wherein 0<n≦10, and is a stabile, physiologically compatible formulation containing said choline pyruvate, water and/or an organic solvent such as glycerine, or is present in a solid and preferably a powder form. The invention also relates to a method for producing choline pyruvate, whereby choline hydroxide is placed in a solvent, such as water or a methanol/water mixture, at a temperature of between 0 and 98° C., then pyruvric acid is added drop by drop in external cooling conditions and mixed until a pH value of between 5.0 and 8.0 is reached, the solvent is then removed and finally the obtained product is added to a physiologically compatible solvent.
Type:
Application
Filed:
June 20, 2003
Publication date:
January 8, 2004
Inventors:
Ralf Jager, Martin Purpura, Gunter Ortenburger, Ivo Pischel
Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Type:
Grant
Filed:
February 11, 2002
Date of Patent:
January 6, 2004
Assignee:
Wyeth
Inventors:
Anthony F. Hadfield, Syed M. Shah, Michael W. Winkley, Karen W. Sutherland, James A. Provost, Aeri Park, Rex A. Shipplett, Brenton W. Russell, Beat T. Weber
Abstract: The invention relates to novel pharmaceutical compositions useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD).
Type:
Application
Filed:
November 15, 2002
Publication date:
December 25, 2003
Inventors:
Eva Trofast, Karin Malmqvist-Granlund, Per-Gunnar Nilsson, Kyrre Thalberg
Abstract: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.
Abstract: 2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory pathologies (particularly septic shock) and/or autoimmune pathologies in which the aetiopathogenic role of inflammatory cytokines has been ascertained.
Abstract: A new cosmetic ingredient, composition and method for cosmetically treating skin is provided which utilizes mono-hydroxy substituted amine salts of malonic acid. Particularly preferred are dimethylaminoethanol (DMAE) salts of malonic acid.
Type:
Application
Filed:
January 21, 2003
Publication date:
December 4, 2003
Applicant:
Unilever Home & Personal Care USA, Division of Conopco, Inc.
Inventors:
Joseph Raymond Faryniarz, Anthony William Johnson, Michael Charles Cheney, Timothy Michael Anto
Abstract: Metformin salts of lipophilic acids, their pharmaceutical formulations, and methods of administrating the metformin salts for the treatment of hyperglycemia.
Type:
Application
Filed:
February 14, 2003
Publication date:
November 27, 2003
Applicant:
Sonus Pharmaceuticals, Inc.
Inventors:
Manjari Lal, Nagesh Palepu, Dean Kessler
Abstract: Derivatives of active ingredients with creatine and ornithine are disclosed having enhanced nutritional and/or therapeutic effects which favorably lend themselves to the preparation of orally administrable solid compositions.
Abstract: The present invention relates to a cosmetic composition containing mineral water and one or more compounds selected from the group of creatine, pyruvic acid, and carnitine, and cosmetically acceptable salt or ester thereof.
Type:
Grant
Filed:
June 29, 2000
Date of Patent:
November 18, 2003
Assignee:
Johnson & Johnson Consumer Companies, Inc.
Inventors:
Stanley S. Shapiro, Steven A. Shaya, Claudia K. Kaminski
Abstract: Described herein are compositions comprising short and long chain fatty acids which are suitable for oral administration, wherein the compositions are useful for the management of body weight. For example, as described, body weight management may be effected via induction of satiety, by using a composition of the present invention.
Type:
Application
Filed:
August 7, 2002
Publication date:
October 30, 2003
Inventors:
Gary Robert Kelm, Jeffrey Warren Clymer, Satinder Singh Bharaj, Mary Ann Starcher, Cynthia Elodi Francis
Abstract: N-Substituted glucamine compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
Type:
Application
Filed:
December 17, 2002
Publication date:
October 16, 2003
Applicant:
Pharmacia Corporation
Inventors:
Richard A. Mueller, Martin L. Bryant, Richard A. Partis
Abstract: Venlafaxine besylate compounds provide certain advantages over venlafaxine hydrochloride and are useful in forming pharmaceutical compositions and n treating venlafaxine-treatable diseases and conditions. Venlafaxine besylate can be easily formulated into an extended release dosage form including a hydrogel tablet as well as other matrix-based tablet compositions. A preferred tablet making process involves hot melt granulation.
Type:
Application
Filed:
March 27, 2003
Publication date:
October 16, 2003
Applicant:
SYNTHON BV
Inventors:
Rolf Keltjens, Johannes Jan Platteeuw, Juan Cucala Escoi, Inocencia Margallo Lana, Frantisek Picha, Montserrat Gallego Luengo
Abstract: The invention relates to aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.
Type:
Application
Filed:
April 8, 2003
Publication date:
September 25, 2003
Applicant:
Orion Corporation
Inventors:
Kaija Af Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Gunilla Orn, Juha Kiesvaara
Abstract: A topical clotting ointment in which cumin in powder form or in oil form is a blood clotter in combination with an unctuous host substance and one or more infection-specific antiseptics and odorants. Method for manufacture includes processing for suspension of the cumin in the host substance and putting it preferably in a squeezable-tube dispenser (7) having an airtight cap (8).
Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid and 20-, 21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z), 15(Z)-dienoic acid.
Type:
Grant
Filed:
December 14, 2001
Date of Patent:
August 12, 2003
Assignee:
MCW Research Foundation
Inventors:
Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder